Cancer immunotherapy in elderly patients: The concept of immune senescence challenged by clinical experience
Authors:
- 23 November 2024
- journal article
- research article
- Published by Elsevier in European Journal of Cancer
- Vol. 214, 115145
Abstract
No abstract availableKeywords
This publication has 77 references indexed in Scilit:
- Glofitamab in relapsed/refractory diffuse large B‐cell lymphoma: Real‐world dataHematological Oncology, 2023
- Safety and Efficacy of BCMA CAR-T Cell Therapy in Older Patients With Multiple MyelomaTransplantation and Cellular Therapy, 2023
- Biomarkers of response to immunotherapy in early stage non-small cell lung cancerEuropean Journal of Cancer, 2023
- Age-associated remodeling of T cell immunity and metabolismCell Metabolism, 2022
- The efficacy of immune checkpoint inhibitors in elderly patients: a meta-analysis and meta-regressionESMO Open, 2022
- Current state and next-generation CAR-T cells in multiple myelomaBlood Reviews, 2022
- Efficacy and safety of immune checkpoint inhibitors in elderly patients with metastatic renal cell carcinomaInternational Urology and Nephrology, 2021
- Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design studyThe Lancet, 2020
- CAR-T design: Elements and their synergistic functionEBioMedicine, 2020
- Cancer immunotherapy: Pros, cons and beyondBiomedicine & Pharmacotherapy, 2020